Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPI1 | P60174 | 2/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | PGK2 | P07205 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 1/20 | 0.37 |
| ▸ | PGD | P52209 | 3/20 | 0.36 |
| ▸ | MPI | P34949 | 1/20 | 0.36 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL22469981 | 0.97 | TPI1 (0.39) | TPI1FDPSBLMTDP1LPAR3 | |
| SCHEMBL533763 | 0.86 | FDPS (0.44) | TPI1FDPSBLMTDP1LPAR3 | |
| SCHEMBL13265240 | 0.83 | — | — | |
| SCHEMBL21332811 | 0.83 | — | — | |
| SCHEMBL27714805 | 0.83 | TPI1 (0.42) | TPI1FDPSBLMTDP1LPAR3 | |
| Water SCHEMBL27700129 | 0.83 | TPI1 (0.42) | TPI1FDPSBLMTDP1LPAR3 | |
| Phosphoric Acid SCHEMBL28705667 | 0.83 | TPI1 (0.42) | TPI1FDPSBLMTDP1LPAR3 | |
| SCHEMBL28770806 | 0.83 | TPI1 (0.42) | TPI1FDPSBLMTDP1LPAR3 | |
| SCHEMBL28107423 | 0.83 | TPI1 (0.42) | TPI1FDPSBLMTDP1LPAR3 | |
| SCHEMBL29216424 | 0.83 | TPI1 (0.42) | TPI1FDPSBLMTDP1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941897-A1 | LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY | Integrated Nanotherapeutics Inc. (CA) | 2022-01-26 | — | — | EP | claimed |
| CN-113853368-A | Lipid conjugates prepared from scaffold moieties | 集成纳米治疗股份有限公司 | 2021-12-28 | — | — | CN | claimed |
| WO-2020191477-A1 | LIPID CONJUGATE PREPARED FROM SCAFFOLD MOIETY | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2020-10-01 | — | — | WO | claimed |
| JP-7002885-A | — | — | None | — | — | JP | disclosed |
| WO-2025123147-A1 | TOLERIZING IMMUNOMODULATORY COMBINATION | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2025-06-19 | — | — | WO | disclosed |
| US-20240374734-A1 | Immunomodulatory Combinations of Antigen and Drug-Lipid Conjugate | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2024-11-14 | — | — | US | disclosed |
| EP-4398930-A1 | IMMUNOMODULATORY COMBINATIONS OF ANTIGEN AND DRUG-LIPID CONJUGATE | Integrated Nanotherapeutics Inc. (CA) | 2024-07-17 | — | — | EP | disclosed |
| CN-118215496-A | Immunomodulatory combinations of antigens and drug-lipid conjugates | 集成纳米治疗股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117999258-A | GPR52 modulator compounds | 赫普泰雅治疗有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM PHARMA SA (CH) | 2023-05-18 | — | — | US | disclosed |
| WO-2023035068-A1 | IMMUNOMODULATORY COMBINATIONS OF ANTIGEN AND DRUG-LIPID CONJUGATE | INTEGRATED NANOTHERAPEUTICS INC. (CA) | 2023-03-16 | — | — | WO | disclosed |
| JP-H072885-A | PHOSPHONOOXYMETHYL ETHER OF TAXANE DERIVATIVE | BRISTOL MYERS SQUIBB CO | 1995-01-06 | — | — | JP | disclosed |
| EP-0626953-A1 | NOVEL SIDECHAIN-BEARING TAXANES AND INTERMEDIATES THEREOF | Bristol-Myers Squibb Company (US) | 1994-12-07 | — | — | EP | disclosed |
| CN-1093369-A | Phosphonooxymethyl ether derivatives of taxanes | BRISTOL MYERS SQUIBB CO (US) | 1994-10-12 | — | — | CN | disclosed |
| CN-1093369-A | Phosphonooxymethyl ether derivatives of taxanes | BRISTOL MYERS SQUIBB CO (US) | 1994-10-12 | — | — | CN | disclosed |
| CN-1093369-A | Phosphonooxymethyl ether derivatives of taxanes | BRISTOL MYERS SQUIBB CO (US) | 1994-10-12 | — | — | CN | disclosed |
| WO-1994014787-A1 | NOVEL SIDECHAIN-BEARING TAXANES AND INTERMEDIATES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-07-07 | — | — | WO | disclosed |
| EP-0604910-A1 | Phosphonooxymethyl ethers of taxane derivatives | Bristol-Myers Squibb Company (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0604910-A1 | Phosphonooxymethyl ethers of taxane derivatives | Bristol-Myers Squibb Company (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0604910-A1 | Phosphonooxymethyl ethers of taxane derivatives | Bristol-Myers Squibb Company (US) | 1994-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | HRH4, NCOA4, HRH3 | TPI1 3843/4885FDPS 2263/4885BLM 652/4885 |
| US-20240374734-A1 | Immunomodulatory Combinations of Antigen and Drug-Lipid Conjugate | LY96, CD74, TLR9 | TPI1 3422/4885FDPS 2883/4885BLM 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.